Showing posts with label Epilepsy. Show all posts
Showing posts with label Epilepsy. Show all posts

Saturday, 20 July 2013

Predicting surgical outcome for epilepsy patients

Main Category: Epilepsy
Article Date: 20 Jul 2013 - 0:00 PDT Current ratings for:
Predicting surgical outcome for epilepsy patients
not yet ratednot yet rated

Scientists at Bonn University Hospital and at the Max Planck Institute for neurological research in Cologne have developed a method with which the chances of success of a surgical procedure for temporal lobe epilepsy can be accurately predicted. The rate of accurate predictions is more than 90%. The results are now being presented in the scientific journal NeuroImage:Clinical.

When many nerve cells simultaneously fire in the brain, an epileptic seizure results. The most frequent form is temporal lobe epilepsy. It originates in one of the two temporal lobes which contain, among other things, important structures for coordinating memory. Because many patients do not respond to medication over the long term, the seizure focus in the affected temporal lobe is often removed in a neurosurgical procedure. However, approximately one-third of patients who undergo surgery do not experience any subsequent improvement. "The procedure is associated with risks - therefore a reliable prognosis regarding the chances of success is very important," says Prof. Dr. Bernd Weber from the Department of Epileptology of Bonn University Hospital.

An Algorithm Assesses Patients' Brain Images

At the Life&Brain Center, the Bonn epilepsy specialists, together with scientists from the Max Planck Institute for Neurological Research in Cologne, have found a way for the chances of success of a temporal lobe procedure in epilepsy patients to be predicted with a striking degree of accuracy. The researchers used images from magnetic resonance imaging from a total of 49 epilepsy patients who had previously undergone surgical removal of the seizure focus in the left temporal lobe. Using a special computer program developed by Lisa Feis from the Max Planck Institute as a part of her dissertation, the scientists looked at the brain images for differences between the patient group whose seizures had improved following surgery and those with unchanged symptoms. "Using brain images, we trained the algorithm to differentiate in the best possible way between seizure-free and non-seizure-free patients," reports Prof. Weber.

Hitting the Mark with Striking Accuracy

Using the algorithm results, the scientists then calculated the chances of success of an intervention and compared them with the actual findings after the surgery. Because the brains of women and men differ, for example in the symmetry of the halves of the brain, the researchers evaluated the data according to gender. The rate of accurate predictions was 96% in the case of female patients and 94% in the case of male patients.

Additional Research Needed

The tests have been performed retrospectively to date: The researchers applied the method retrospectively on patients who have already undergone surgery. As the next step, the scientists want to examine how well the method predicts chances of success in epilepsy patients who still have yet to undergo a procedure on the temporal lobe. Other university medical centers and even more detailed imaging procedures will be included in this. "At present, we are still at a stage that is too early for clinical application; further research is needed," says Prof. Dr. Christian Elger, director of the Bonn Epilepsy Clinic.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our epilepsy section for the latest news on this subject.

Publication: Prediction of post-surgical seizure outcome in left mesial temporal lobe epilepsy, Journal "NeuroImage:Clinical", DOI: 10.1016/j.nicl.2013.06.010 Internet: http://www.sciencedirect.com/science/article/pii/S2213158213000788

University of Bonn

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

University of Bonn. "Predicting surgical outcome for epilepsy patients." Medical News Today. MediLexicon, Intl., 20 Jul. 2013. Web.
20 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Predicting surgical outcome for epilepsy patients'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Sunday, 14 July 2013

Swissmedic Approves Zonegran® (Zonisamide) Monotherapy Treatment For Epilepsy

Main Category: Epilepsy
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 12 Jul 2013 - 2:00 PDT Current ratings for:
Swissmedic Approves Zonegran® (Zonisamide) Monotherapy Treatment For Epilepsy
not yet ratednot yet rated

Zonegran(R) (zonisamide) has been approved by Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, for the monotherapy treatment of partial seizures (with or without secondary generalisation) in adults with newly diagnosed epilepsy. Monotherapy is when treatment is given with one single drug.

Already a successful add-on therapy, once-daily zonisamide is a second generation anti-epileptic drug (AED) with multiple mechanisms of action and a chemical structure which is unrelated to any other AEDs.[1] For patients with newly diagnosed epilepsy, monotherapy is the preferred option for managing their condition as this reduces the potential for adverse drug interactions and encourages treatment compliance.[2]

"Monotherapy is the optimal treatment approach for managing epilepsy and therefore the availability of zonisamide in this setting will provide newly diagnosed epilepsy patients with access to this already proven treatment as a first-line option in their care pathway," commented Professor Michel Baulac, Head of Neurology, Université Paris VI.

Epilepsy is one of the most common neurological conditions in the world[3] with an estimated 70,000 people living with the condition in Switzerland alone[4]. The successful treatment of partial-onset seizures (the most common type of epilepsy) remains a significant challenge and up to 30% of patients fail to achieve seizure freedom with existing AEDs[5].

"The approval of zonisamide monotherapy in Switzerland is a very welcome advance for both doctors and patients. The new extended monotherapy indication for Zonegran will provide patients with an alternative option to help improve their seizure control. The monotherapy indication will become an increasingly important option in the early treatment of partial epilepsy," said Dr. Christiane Kordeuter, Medical Director, Eisai Switzerland. "Zonegran is one of only six AEDs available as monotherapy, allowing doctors to tailor treatment to individual patient needs."

The efficacy and safety of zonisamide as monotherapy has been demonstrated in a double-blind, randomised, multicentre study of 583 newly diagnosed adult partial epilepsy patients, which compared the efficacy and safety of once-daily zonisamide with twice-daily controlled release carbamazepine as monotherapy. The study's primary endpoint was the proportion of seizure-free patients at six months. Zonisamide demonstrated high response rates for achieving seizure freedom in newly diagnosed patients with epilepsy,[6] similar to controlled release carbamazepine. In the majority of patients, seizure freedom was achieved at the target dose of 300 mg. Zonisamide was considered non-inferior to carbamazepine, was well tolerated and had no apparent safety concerns after one year of treatment at doses ranging from 300 to 500 mg/day.

The continued development of zonisamide underscores Eisai's human health care mission, the company's commitment to innovative solutions in disease prevention, cure and care for the health and well being of people worldwide. Eisai is committed to the therapeutic area of epilepsy and addressing the unmet medical needs of patients with epilepsy and their families. Eisai is proud to currently market more epilepsy products in EMEA than any other company.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our epilepsy section for the latest news on this subject.

1. Zonegran Summary of Product Characteristics

2. St. Louis, K. Rosenfeld. W. Bramley, T. Antiepileptic Drug Monotherapy: The Initial Approach in Epilepsy Management (2009) &(2): 77 - 72

3. ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe 2010 (Accessed June 2011)

4. EPI Swiss Epilepsy Centre (Accessed August 2011)

5. Kwan P, Brodie MJ Early identification of refractory epilepsy. New England Journal of Medicine 2000; 342:314-9

6. Baulac, M. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurology (2012), 11 (7) 579 - 588

Eisai

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Eisai. "Swissmedic Approves Zonegran® (Zonisamide) Monotherapy Treatment For Epilepsy." Medical News Today. MediLexicon, Intl., 12 Jul. 2013. Web.
14 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Swissmedic Approves Zonegran® (Zonisamide) Monotherapy Treatment For Epilepsy'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here